Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
Florida Ruling Upholds GSK's Stance On Once Popular Heart Burn Drug Zantac Not Being Associated With Cancer Risk
In a significant legal win for GSK plc (NYSE:GSK), on Friday, a Florida State Court ruled in favor of the pharmaceutical giant, excluding the plaintiff's expert testimonies that claimed ranitidine, a drug once sold under the Zantac brand, was a significant risk factor for prostate cancer.
週五，佛羅里達州一家州法院對藥品巨頭葛蘭素史克（NYSE: GSK）做出了重大勝利的裁決，剔除了原告的專家證言。原告聲稱，曾經銷售的醫藥品牌贊替丁是攀升前列腺癌風險的一個重要因素。
The court deemed the expert testimony unreliable, reinforcing the broader scientific consensus that ranitidine does not pose a consistent or reliable cancer risk.
法院認定專家證言不可靠，進一步強化了更廣泛的科學共識：贊替丁並不會帶來一致或可靠的癌症風險。
This decision aligns with a December 2022 ruling by Judge Rosenberg in the federal multidistrict litigation (MDL), which also dismissed expert evidence brought by plaintiffs alleging a link between ranitidine and several cancers, including bladder, esophageal, gastric, liver, and pancreatic cancers.
此次裁決與2022年12月羅森伯格（Rosenberg）法官在聯邦多區域訴訟（MDL）中做出的裁決一致。該裁決也駁回了原告提出的專家證據，聲稱讚替丁和多種癌症（包括膀胱癌、食道癌、胃癌、肝癌和胰腺癌）之間存在聯繫。
Also Read: Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer.
另外閱讀消息：行業板塊支持葛蘭素史克努力停止與胃酸反流藥贊替丁有關的70,000起引發癌症的訴訟。
Both the Florida and MDL courts concluded that the methodologies used by plaintiffs' experts did not meet the Daubert standard, a key legal benchmark for scientific evidence.
佛羅里達州和聯邦MDL法院均得出結論，原告專家所使用的方法未達到道伯特標準，這是科學證據的關鍵法律基準。
The scientific consensus, based on 16 epidemiological studies examining ranitidine use, has consistently shown no reliable evidence linking the drug to cancer risk.
基於16項以贊替丁用藥爲研究對象的流行病學研究，在科學共識的基礎上，一致表明贊替丁與癌症風險沒有可靠的證據關聯。
The Florida State Court's ruling reflects this stance and safeguards against what GSK argues is "litigation-driven" science from entering legal proceedings.
佛羅里達州法院的裁決反映了這一立場，並防範了葛蘭素史克所認爲的「以訴訟爲驅動」的科學進入法律程序。
GSK welcomed the ruling, stating it would now seek the dismissal of the upcoming Wilson case in Florida, where similar allegations about ranitidine and prostate cancer had been made.
葛蘭素史克對此裁決表示歡迎，並表示將尋求不予受理即將在佛羅里達州開庭的威爾遜案。威爾遜案相似，是有關贊替丁和前列腺癌的指控。
Earlier this month, Jury in the Joiner case in Illinois state court found GSK not liable for the plaintiff's colorectal cancer.
本月早些時候，伊利諾伊州法院的喬伊納案陪審團判定，葛蘭素史克不承擔原告的結腸癌責任。
In July, GSK reached a confidential settlement with Ronald Kimbrow, resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement.
今年7月，葛蘭素史克與羅納德·金布羅（Ronald Kimbrow）達成機密和解，解決了他在伊利諾伊州法院提起的案件。在此和解中，葛蘭素史克不承認任何責任。
The case was dismissed.
此案已被解散。
According to a May report, Pfizer Inc. (NYSE:PFE) settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, marking the largest resolution in the litigation.
根據5月的一份報告，輝瑞公司（NYSE:PFE）已和解了1萬起指控其隱瞞贊替丁胃酸反流藥有癌症風險的訴訟，這標誌着該訴訟的最大解決方案。
In April, Sanofi SA (NASDAQ:SNY) announced an agreement in principle to settle approximately 4,000 lawsuits in the U.S. linked to the discontinued heartburn drug Zantac.
今年4月，法國賽諾菲安萬特公司（Sanofi SA，納斯達克代碼：SNY）宣佈原則上同意解決併購有關停售的胃酸反流藥贊替丁的約4,000起訴訟。
Price Action: GSK stock is down 0.56% at $41.17 during the premarket session at last check Friday.
週五盤前，葛蘭素史克股價爲41.17美元，下跌0.56%。
- Oral Vaccine-Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside.
- 口服疫苗針對的便宜股票Vaxart處境獨特，分析師預計漲幅近83%。
Photo by ParentingPatch via Wikimedia Commons
圖片由ParentingPatch通過維基媒體公共領域共享許可證發佈。